🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Innova Captab Limited INNOVACAP NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://innovacaptab.com
Company Profile ↓
₹1,013.55
+17.24% 1Y
Mkt Cap₹5,800.03 Cr
P/E41.15
P/B5.25
Div. Yield0.40%
52W High₹1,013.55
52W Low₹642.85
Book Value₹190.61
EPS (TTM)₹24.63

Company Overview

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors, stockists, and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.3%.

Consistent Profit Growth

Net profit has compounded at 27.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 20.1% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.32.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹1,603.91 Cr (+29.9% YoY); net profit ₹140.92 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +29.9%, earnings +9.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 20.1%, profit CAGR 27.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:20.12%
1 Year:29.93%

Compounded Profit Growth

5 Years:27.52%
1 Year:9.87%

Stock Price Performance

1 Year:+17.24%
6 Months:+39.26%
3 Months:+37.96%
1 Month:+6.92%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹642.85 ₹1,013.55
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)69.98 · Neutral
Price Performance
1M+6.92%
3M+37.96%
6M+39.26%
1Y+17.24%
Valuation vs Sector

P/E of 41.15 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 20.1% over 5 years.
  • Profit CAGR of 27.5% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
41.15
Industry PE
39.97
Forward P/E
22.57
PEG Ratio
-
Book Value
₹190.61
Price to Book
5.25
P/S
3.51
EV/EBITDA
25.99
Dividend Yield
0.40%

Growth (CAGR)

Revenue 5Y
20.12%
Profit 5Y
27.52%
Revenue (YoY)
29.93%
Earnings (YoY)
9.87%

Profitability & Returns

ROCE
15.26%
ROE
12.92%
ROA
7.67%
Profit Margin
8.79%
Op Margin
11.67%
Gross Margin
32.60%
EPS (Latest Qtr)
₹6.65
EPS (TTM)
₹24.63

Balance Sheet & Liquidity

Debt/Equity
0.32
Quick Ratio
1.29
Current Ratio
1.87
Debt
₹343.69 Cr
Total Assets
₹1,837.38 Cr
Current Assets
₹922.96 Cr
Working Capital
₹428.38 Cr

Ownership

Promoter Holding
72.19%
Chg in Prom Hold
21.29%
FII / Inst Holding
18.83%
Chg in FII Hold
-0.60%

Financial Snapshot

Enterprise Value
₹5,800.03 Cr
Total Revenue (TTM)
₹1,603.91 Cr
EBITDA
₹250.13 Cr
Free Cash Flow
₹48.16 Cr
Operating Cash Flow
₹116.52 Cr
Shares Outstanding
₹5.72 Cr
Gross Margin
32.60%
Payout Ratio
8.12%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 INNOVACAP Innova Captab Limited NSEPHARMA 1,013.55 41.15 ₹5,800.03 Cr 0.40% 15.26% 12.92% 20.12% 27.52%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 241.00 Cr233.00 Cr283.00 Cr302.00 Cr263.00 Cr294.00 Cr318.00 Cr316.00 Cr314.74 Cr351.54 Cr380.38 Cr450.29 Cr447.80 Cr
Cost of Revenue --------198.02 Cr220.74 Cr243.58 Cr291.82 Cr296.66 Cr
Gross Profit --------116.72 Cr130.80 Cr136.80 Cr158.48 Cr151.15 Cr
Operating Expenses 214.00 Cr202.00 Cr242.00 Cr258.00 Cr225.00 Cr252.00 Cr268.00 Cr270.00 Cr78.83 Cr89.75 Cr96.26 Cr100.50 Cr97.44 Cr
Operating Income 24.00 Cr28.00 Cr35.00 Cr40.00 Cr35.00 Cr37.00 Cr45.00 Cr42.00 Cr37.88 Cr41.05 Cr40.54 Cr57.97 Cr53.70 Cr
EBITDA 27.00 Cr31.00 Cr40.00 Cr45.00 Cr38.00 Cr42.00 Cr50.00 Cr47.00 Cr51.06 Cr56.58 Cr56.05 Cr71.05 Cr66.66 Cr
Interest Expense 5.00 Cr5.00 Cr9.00 Cr7.00 Cr1.00 Cr0001.95 Cr2.86 Cr5.50 Cr3.95 Cr4.59 Cr
Pretax Income 21.00 Cr25.00 Cr30.00 Cr35.00 Cr40.00 Cr39.00 Cr47.00 Cr46.00 Cr39.31 Cr42.68 Cr39.23 Cr55.68 Cr50.67 Cr
Tax Provision 3.99 Cr7.00 Cr7.20 Cr10.15 Cr10.80 Cr9.75 Cr11.75 Cr11.50 Cr9.74 Cr11.66 Cr9.56 Cr13.53 Cr12.59 Cr
Net Income 17.00 Cr18.00 Cr23.00 Cr25.00 Cr29.00 Cr29.00 Cr35.00 Cr34.00 Cr29.57 Cr31.02 Cr29.67 Cr42.15 Cr38.08 Cr
Diluted EPS 3.593.664.774.395.025.156.125.985.175.425.187.376.65

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 356.00 Cr373.00 Cr411.00 Cr801.00 Cr925.40 Cr1,076.96 Cr1,234.42 Cr1,603.91 Cr
Cost of Revenue ----701.08 Cr750.51 Cr838.04 Cr1,081.03 Cr
Gross Profit ----224.31 Cr326.45 Cr396.39 Cr522.88 Cr
Operating Expenses 315.00 Cr322.00 Cr356.00 Cr704.00 Cr119.16 Cr184.92 Cr230.93 Cr335.67 Cr
Operating Income 30.00 Cr41.00 Cr48.00 Cr88.00 Cr105.16 Cr141.53 Cr165.46 Cr187.21 Cr
EBITDA 41.00 Cr51.00 Cr54.00 Cr96.00 Cr121.81 Cr166.68 Cr198.04 Cr250.13 Cr
Interest Expense 6.00 Cr5.00 Cr4.00 Cr6.00 Cr18.94 Cr21.20 Cr2.24 Cr16.69 Cr
Pretax Income 25.00 Cr38.00 Cr46.00 Cr86.00 Cr91.80 Cr129.53 Cr171.02 Cr188.26 Cr
Tax Provision 5.00 Cr9.88 Cr11.96 Cr21.50 Cr23.84 Cr35.18 Cr42.76 Cr47.35 Cr
Net Income 20.00 Cr28.00 Cr34.00 Cr64.00 Cr67.95 Cr94.34 Cr128.26 Cr140.92 Cr
Diluted EPS 165.67232.42287.50532.9211.8718.6622.4124.63

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 223.00 Cr245.00 Cr370.00 Cr-704.41 Cr1,320.88 Cr1,580.41 Cr1,837.38 Cr
Current Assets ----442.47 Cr579.75 Cr703.11 Cr922.96 Cr
Cash & Equivalents ----3.52 Cr11.73 Cr15.52 Cr3.20 Cr
Inventory ----117.32 Cr144.02 Cr208.00 Cr283.26 Cr
Receivables ----265.22 Cr288.49 Cr331.64 Cr437.29 Cr
Total Liabilities ----427.91 Cr489.99 Cr620.99 Cr746.59 Cr
Current Liabilities ----277.55 Cr265.48 Cr353.00 Cr494.58 Cr
Long Term Debt ----134.18 Cr208.20 Cr243.55 Cr214.80 Cr
Total Debt 72.00 Cr54.00 Cr46.00 Cr-236.97 Cr245.10 Cr338.12 Cr343.69 Cr
Total Equity 82.00 Cr110.00 Cr145.00 Cr-276.51 Cr830.89 Cr959.42 Cr1,090.79 Cr
Shares Outstanding ----5.72 Cr5.72 Cr5.72 Cr5.72 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 19.00 Cr31.00 Cr42.00 Cr-67.12 Cr146.34 Cr63.84 Cr116.52 Cr
Investing Cash Flow -9.00 Cr-6.00 Cr-20.00 Cr--90.84 Cr-498.97 Cr-151.59 Cr-107.12 Cr
Financing Cash Flow -9.00 Cr-23.00 Cr-19.00 Cr-27.09 Cr360.83 Cr91.53 Cr-21.71 Cr
Capital Expenditure -8.00 Cr-4.00 Cr-19.00 Cr--78.99 Cr-287.35 Cr-172.50 Cr-68.35 Cr
Free Cash Flow 11.00 Cr27.00 Cr23.00 Cr--11.87 Cr-141.01 Cr-108.65 Cr48.16 Cr
Net Change in Cash 1.00 Cr1.00 Cr3.00 Cr-3.37 Cr8.20 Cr3.79 Cr-12.32 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----24.2%30.3%32.1%32.6%
Operating Margin % 8.4%11.0%11.7%11.0%11.4%13.1%13.4%11.7%
Net Margin % 5.6%7.5%8.3%8.0%7.3%8.8%10.4%8.8%
ROE % 24.4%25.5%23.4%-24.6%11.4%13.4%12.9%
ROCE % ----24.6%13.4%13.5%13.9%

Shareholding Pattern

Insiders
72.19%
Institutions
18.83%
Public Float
67.71%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INNOVACAP

Google News ue, 12 May 2026

Innova Captab Limited (NSE:INNOVACAP) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOcHJQUDFiZHlNZmVHUUdPWllTZ3BoWXpGUTc2Qk1NM3kxa2FZN0hqVlZKZEZibnF1VV9xeGFJMzhmM0RxVFBtYmlPVVJXbzdRUklnUGc3RVU2cUJCWnV2aFZKVlltRzVEMDVVM2R3alg3ZGR0LUNXNWFLRElDUkhTN0taYnZxUmU1dEpmZl…

Google News Wed, 12 Nov 2025

Innova Captab Limited (NSE:INNOVACAP) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPYjZhQ3AzTTdnUGZiX2JoX2Jvd01Nb0l3NzhxTzdETTktYXhScnUzbW55LUJPWHZIUlAxM1hnSU9MVXp4M1l4c0xYUTFjOUl4eEVXZkhZWFRGa1FQWkJ1M1ROWk0wbVFGUzJCbTF2TThsSkhoQ2FDWXNRN1MxTWZfcTBNanhNbTltWFRoR3…

Google News Fri, 29 Dec 2023

INNOVACAP Stock Price and Chart — NSE:INNOVACAP - TradingView

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBNNFFONmMxVzZiV1l1Vy1RTDZnelhZSU1TbTNZRlVTdEZoUUJHaFd3V0x5TFlVdTNjejk0eFdNaTBiOE53dWg3c1ZsYUNIOGFPM3BSR3ZzeEI1WE5NbkFr?oc=5" target="_blank">INNOVACAP Stock Price and Chart — NSE:I…

Google News hu, 13 Nov 2025

Analysts Just Slashed Their Innova Captab Limited (NSE:INNOVACAP) EPS Numbers - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOWjhYcGhmRjU2Y2FrNW5Fd1pIMmRPVjB6bHFoTWZ0YUpSOENFMXVIOHVEdEhmNTdtWHhocjEwYkNhOEpoQzVPZThHbFZram05NXZ1Ny1mX3BObUVIeUhTaEtfdFFibDFkX0RpMjQ4T2NaOV9WNUFMVkJPLXlMcFRRWTFBZGxxUGdieFoybn…

Google News Sat, 03 Jan 2026

Innova Captab Ltd. Share Price Today - Innova Captab Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxNLWRpMU82aXBnVEZHNGtlU3BMbkt4c054WGJyMzhQWHF4RWRNWWtVN1hQZFZYZTRCZFRoSThoUUVFMUxlT2VFTWtiejVPMHBKUDFpMWhqeDYxRXdjNmpTdVM3RmFDeERjTmZGUmEtb1JZOTctZjJQTFpVRWJxN1Q0Zw?oc=5" target="_…

Google News Fri, 29 Dec 2023

Innova Captab Ltd Share Price Today | Innova Captab Live NSE/BSE - Value Research

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5ER3FkRHJ2b3NoWVRodkVEd042Y1hZeF9leldpZHZaWmtncnFNSU0zcVp6S3BxZGhCX3dZSlpqZFJzWkJhSmMxdUtBNGRfSEFmZlBpV0ZHZzlzNXY4ckIzNm5zTG1BQXpUSDBVcnhQSElRMEJmVFBZ?oc=5" target="_blank">Innova …

INNOVACAP — Frequently Asked Questions

What is the current share price of Innova Captab Limited (INNOVACAP)?

As of 2026-07-15 09:52 IST, Innova Captab Limited (INNOVACAP) trades at ₹1,013.55 on NSE. Its 52-week range is ₹642.85 to ₹1,013.55.

What is the market capitalisation of INNOVACAP?

Innova Captab Limited (INNOVACAP) has a market capitalisation of ₹5,800.03 Cr on NSE.

What is the P/E ratio of INNOVACAP?

INNOVACAP trades at a trailing price-to-earnings (P/E) ratio of 41.15. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.25.

Does INNOVACAP pay a dividend?

Innova Captab Limited (INNOVACAP) currently offers a dividend yield of 0.40%.

What is the return on equity (ROE) of INNOVACAP?

INNOVACAP has a return on equity (ROE) of 12.92%. Its return on capital employed (ROCE) is 15.26%.

Is INNOVACAP a good stock to buy?

This page provides a data-driven analysis of Innova Captab Limited (INNOVACAP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space